|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95.40 USD | +3.49% |
|
+1.36% | -23.86% |
| 03/07 | Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula | RE |
| 03/07 | Reckitt unit Mead Johnson not liable in latest preterm baby formula trial, company says | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 166,169 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -23.73% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 177,858 | 175,026 | 171,127 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -19.98% | -1.59% | -2.23% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 23.6x | 20.1x | 17.5x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.36x | 3.22x | 3x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | 2.72x | 1.2x | 1.2x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.31x | 3.04x | 2.83x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.54x | 3.2x | 2.92x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 13.3x | 12x | 10.7x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 15.2x | 13.4x | 11.9x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 20.5x | 18.6x | 16.5x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 4.87% | 5.39% | 6.07% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.547 | 2.715 | 2.866 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.67% | 2.85% | 3% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 4.043 | 4.736 | 5.437 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 63% | 57.3% | 52.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,257 | 54,749 | 58,634 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,388 | 14,551 | 15,928 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,665 | 13,038 | 14,362 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 7,018 | 8,389 | 9,226 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 11,689 | 8,857 | 4,959 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 95.40 | 95.40 | 95.40 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,741,813 | - | - |
| Announcement Date | 26/1/22 | 25/1/23 | 24/1/24 | 22/1/25 | 22/1/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.6x | 3.54x | 13.29x | 2.67% | 166B | |
| 18.86x | 3.29x | 11.59x | 3.56% | 106B | |
| 16.3x | 0.18x | 11.67x | 0.8% | 57.69B | |
| 32.78x | 7.96x | 20.82x | 1.23% | 53.78B | |
| 39.39x | 3.1x | 10.64x | 2.44% | 43.56B | |
| 41.35x | 1.48x | 13.02x | 0.19% | 36.52B | |
| 29.11x | 5.18x | 16.53x | -.--% | 27.49B | |
| 43.44x | 7.53x | 27.19x | 0.24% | 25.84B | |
| 24x | 3.51x | 12.61x | 1.21% | 21.27B | |
| 19.96x | 2.75x | 10.72x | 1.58% | 20.65B | |
| Average | 28.88x | 3.85x | 14.81x | 1.39% | 55.95B | |
| Weighted average by Cap. | 26.28x | 3.64x | 13.98x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
